Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 815-821

  Davis, Benjamin B ^a,b   Morisseau, Christophe ^b   Newman, John W ^b   Pedersen, Theresa L ^b   Hammock, Bruce D ^b   Weiss, Robert H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ADAMANTYL 3 [5 (2 ETHOXYETHOXY)ETHOXY]PENTYL UREA; 1 ADAMANTYL 3 DODECYL UREA; 1 CYCLOHEXYL 3 DODECYL UREA; 12 (3 ADAMANTYLUREIDO)DODECANOIC ACID BUTYL ESTER; 12 (3 CYCLOHEXYLUREIDO)DODECANOIC ACID; ADAMANTANE DERIVATIVE; BASIC FIBROBLAST GROWTH FACTOR; CARBON; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

AORTA; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE;

AORTA; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSANOIC ACIDS; EPOXIDE HYDROLASES; HUMANS; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 31144468654     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.091876     Document Type: Article

References (36)

1. Borhan B, Mebrahtu T, Nazarian S, Kurth MJ, and Hammock BD (1995) Improved radiolabeled substrates for soluble epoxide hydrolase. Anal Biochem 231:188-200.
2. Carroll MA, Balazy M, Margiotta P, Falck JR, and McGiff JC (1993) Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem 268:12260-12266.
3. Chen JK, Falck JR, Reddy KM, Capdevila J, and Harris RC (1998) Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem 273:29254-29261.
4. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, and Weiss RH (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 99:2222-2227.
5. Escalante B, Erlij D, Falck JR, and McGiff JC (1993) Cytochrome P450-dependent arachidonate metabolites affect renal transport in the rabbit. J Cardiovasc Pharmacol 22 (Suppl 2):S106-S108.
6. Falck JR, Yadagiri P, and Capdevila J (1990) Synthesis of epoxyeicosatrienoic acids and heteroatom analogs. Methods Enzymol 187:357-364.
7. Fang X, Hu S, Watanabe T, Weintraub NL, Snyder GD, Yao J, Liu Y, Shyy JY, Hammock BD, and Spector AA (2005) Activation of peroxisome proliferator- activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314:260-270.
8. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, and Spector AA (2001) Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276:14867-14874.
9. Fang X, Moore SA, Stoll LL, Rich G, Kaduce TL, Weintraub NL, and Spector AA (1998) 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol 275:H2113-H2121.
10. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, and Busse R (2001) The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch Eur J Physiol 442:511-518.
11. Gebremedhin D, Ma YH, Falck JR, Roman RJ, VanRollins M, and Harder DR (1992) Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol 263:H519-H525.
12. Gill SS and Hammock BD (1979) Hydration of cis- and trans-epoxymethyl stearates by the cytosolic epoxide hydrase of mouse liver. Biochem Biophys Res Commun 89:965-971.
13. + exhange and are mitogenic in cultured rat glomerular mesangial cells. J Cell Physiol 144:429-437.
14. Imig JD, Inscho EW, Deichmann PC, Reddy KM, and Falck JR (1999) Afferent arteriolar vasodilation to the sulfonimide analog of 11,12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension 33:408-413.
15. Imig JD, Navar LG, Roman RJ, Reddy KK, and Falck JR (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7:2364-2370.
16. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
17. Jones PD, Wolf NM, Morisseau CH, Whetstone P, Hock B, and Hammock BD (2005) Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem 343:66-75.
18. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, and Fleming I (2005) Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45:759-765.
19. Li PL, Zou AP, and Campbell WB (1997) Regulation of potassium channels in coronary arterial smooth muscle by endothelium-derived vasodilators. Hypertension 29:262-267.
20. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, and Hammock BD (2002) Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63:1599-1608.
21. Newman JW, Watanabe T, and Hammock BD (2002) The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 43:1563-1578.
22. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (Wash DC) 285:1276-1279.
23. Potente M, Fisslthaler B, Busse R, and Fleming I (2003) 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J Biol Chem 278:29619-29625.
24. Potente M, Michaelis UR, Fisslthaler B, Busse R, and Fleming I (2002) Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 277:15671-15676.
25. Proctor KG, Falck JR, and Capdevila J (1987) Intestinal vasodilation by epoxyeicosatrienoic acids: arachidonic acid metabolites produced by a cytochrome P450 monooxygenase. Circ Res 60:50-59.
26. Schmelzer K, Kubala L, Newman JW, Kim IH, Eiserich JP, and Hammock B (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102:9772-9777.
27. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, and Hammock BD (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 102:2186-2191.
28. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, and Liao JK (2002) Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids. Circ Res 90:1020-1027.
29. Weiss RH, Maga EA, and Ramirez A (1998) MEK inhibition augments Raf activity but has variable effects on mitogenesis in vascular smooth muscle cells. Am J Physiol 274:C1521-C1529.
30. Weiss RH and Nuccitelli R (1992) Inhibition of tyrosine phosphorylation prevents thrombin-induced mitogenesis, but not intracellular free calcium release, in vascular smooth muscle cells. J Biol Chem 267:5608-5613.
31. Wixtrom RN, Silva MH, and Hammock BD (1988) Cytosolic epoxide hydrolase in human placenta. Placenta 9:559-563.
32. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, and Weiss RH (2004) Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol 286:F720-F726.
33. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87:992-998.
34. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR, and Capdevila JH (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268:6402-6407.
35. Zhang C and Harder DR (2002) Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke 33:2957-2964.
36. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, and Imig JD (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15: 1244-1253.